Cell-cycle dysregulation and anticancer therapy

Trends Pharmacol Sci. 2003 Mar;24(3):139-45. doi: 10.1016/S0165-6147(03)00026-9.


Cell-cycle dysregulation is a hallmark of tumor cells. The ability of normal cells to undergo cell-cycle arrest after damage to DNA is crucial for the maintenance of genomic integrity. The biochemical pathways that stop the cell cycle in response to cellular stressors are called checkpoints. Defective checkpoint function results in genetic modifications that contribute to tumorigenesis. The regulation of checkpoint signaling also has important clinical implications because the abrogation of checkpoint function can alter the sensitivity of tumor cells to chemotherapeutics. Here, we provide an overview of the mechanisms that regulate the cell cycle, current anticancer therapies that target checkpoint signaling pathways, and strategies for the development of novel chemotherapeutic agents.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Biopharmaceutics / trends*
  • Genes, cdc / drug effects*
  • Humans
  • Neoplasms / drug therapy*
  • Spindle Apparatus / drug effects
  • Spindle Apparatus / physiology*


  • Antineoplastic Agents